Everything below concerns Dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Generalmajor Walter Hörnlein - 1 April 1942 – 3 April 1943 Generalleutnant Hermann Balck - 3 April - 30 June 1943 Generalleutnant Walter Hörnlein - 30 June 1943 - 1 February 1944 Generalleutnant Hasso von Manteuffel - 1 February 1944 – August 1944 Generalmajor Karl Lorenz - 1 September 1944 - 7 May 1945
== Alternate 5-oxo-ETE producing pathways == The immediate metabolic precursor to 5(S)-HETE, 5(S)-hydroperoxy-6S,8Z,11Z,14Z-eicosatetraenoic acid 5(S)-HpETE, can be converted to 5-oxo-ETE in a non-enzymatic dehydration reaction or chemical lipid peroxidation reactions. The physiological occurrence and relevancy of these reaction pathways has not been ascertained.
In 1949, Glenn T. Seaborg, who devised the actinide concept, predicted that element 103 (lawrencium) should be the last actinide and that the Lr3+ ion should be about as stable as Lu3+ in aqueous solution. It was not until decades later that element 103 was finally conclusively synthesized and this prediction was experimentally confirmed. Studies on the element, performed in 1969, showed that lawrencium reacts with chlorine to form a product that was most likely the trichloride, LrCl3. Its volatility was found to be similar to the chlorides of curium, fermium, and nobelium and much less than that of rutherfordium chloride. In 1970, chemical studies were performed on 1500 atoms of 256Lr, comparing it with divalent (No, Ba, Ra), trivalent (Fm, Cf, Cm, Am, Ac), and tetravalent (Th, Pu) elements. It was found that lawrencium coextracted with the trivalent ions, but the short half-life of 256Lr precluded a confirmation that it eluted ahead of Md3+ in the elution sequence. Lawrencium occurs as the trivalent Lr3+ ion in aqueous solution and hence its compounds should be similar to those of the other trivalent actinides: for example, lawrencium(III) fluoride (LrF3) and hydroxide (Lr(OH)3) should both be insoluble in water. Due to the actinide contraction, the ionic radius of Lr3+ should be smaller than that of Md3+, and it should elute ahead of Md3+ when ammonium α-hydroxyisobutyrate (ammonium α-HIB) is used as an eluant.
=== Polymerization === The ring-opening polymerization of butyrolactone gives polybutyrolactone. The resulting reverts to the monomer by thermal cracking. It is claimed that poly(GBL) is competitive with commercial biomaterial poly(4-hydroxybutyrate), or P4HB. It is further claimed that poly(GBL) is cheaper to make than P4HB, although both are bio-derived.
=== The New 52 === Following Mogo's destruction, the Guardians tell John Stewart that Mogo's remains appear to be moving toward a particular location, suggesting that Mogo is trying to reform. The Guardians assign Stewart to track it. While traveling, he encounters Fatality, who reveals that Mogo is actually a male and female consciousness that were 'mated' at the core, with John's fragment of Mogo containing the female consciousness that seeks to be reunited with its mate. This prompts Fatality to use her Star Sapphire powers to help the endangered love come together. John and Fatality arrive at the location of Mogo's pieces. They are held prisoner by a space pirate using Mogo's power as the ship's energy beam weapon to attack the planet's core, threatening their lives. John and Fatality attack the space pirate, intending to free Mogo, by sending the space pirate to crash on the planet. John discovers the Guardians' plan to use Mogo. After the events of "War of the Green Lanterns", Mogo reforms into a planet's orbit. The Guardians reveal their plan was to use the size of the reconstituted Mogo and assimilate it into the Third Army, but the plan fails when Mogo destroys the Third Army trying to assimilate it. The villainous First Lantern drains the Green Lantern Corps of their emotions on the planet Oa, but Mogo rescues the Corps by shielding them with dirt and stone, allowing them to escape. When the Green Lantern Corps are transported to Mogo, Mogo creates a scenario in which the Corps is attacked by their doppelgangers.
Sources: en.wikipedia.org
In flue-gas desulfurization, exhaust gases from fossil-fuel power stations and other processes (e.g. cement manufacture) are scrubbed to reduce their sulfur dioxide content, by injecting finely ground limestone: SO2 + 0.5 O2 + CaCO3 → CaSO4 + CO2 Related sulfur-trapping methods use lime and some produces an impure calcium sulfite, which oxidizes on storage to calcium sulfate.
=== Sahrawi Arab Democratic Republic === The Castillo Administration recognized the Sahrawi Arab Democratic Republic, a partially-recognized state claimed by Morocco. Although the recognition came without forewarning, officially it was due to Castillo's push for a foreign policy based on self-determination and non-intervention. The Congressional opposition has opposed the recognition of the SADR, claiming that it creates geopolitical instability and risks Peru's relations with the Middle East.
== Further reading == Jones, LR; Maddock, SW; Besch, HR Jr (1980). "Unmasking effect of alamethicin on the (Na+,K+)-ATPase, beta-adrenergic receptor-coupled adenylate cyclase, and cAMP-dependent protein kinase activities of cardiac sarcolemmal vesicles". J. Biol. Chem. 255 (20): 9971–9980. doi:10.1016/S0021-9258(18)43488-6. PMID 6253461. Explore structures of Alamethicin at the protein data bank Alamethicin in Norine From "A voltage-gated ion channel model inferred from the crystal structure of alamethicin at 1.5-A resolution." Fox Jr, RO; Richards, FM (1982). "A voltage-gated ion channel model inferred from the crystal structure of alamethicin at 1.5-A resolution". Nature. 300 (5890): 325–30. Bibcode:1982Natur.300..325F. doi:10.1038/300325a0. PMID 6292726. S2CID 4278453. Leitgeb, Balázs; Szekeres, András; Manczinger, László; Vágvölgyi, Csaba; Kredics, László (2007-06-01). "The History of Alamethicin: A Review of the Most Extensively Studied Peptaibol". Chemistry & Biodiversity. 4 (6): 1027–1051. doi:10.1002/cbdv.200790095. ISSN 1612-1880. PMID 17589875. S2CID 40886688.
Umespirone (KC-9172) is a drug of the azapirone class which possesses anxiolytic and antipsychotic properties. It behaves as a 5-HT1A receptor partial agonist (Ki = 15 nM), D2 receptor partial agonist (Ki = 23 nM), and α1-adrenoceptor receptor antagonist (Ki = 14 nM), and also has weak affinity for the sigma receptor (Ki = 558 nM). Unlike many other anxiolytics and antipsychotics, umespirone produces minimal sedation, cognitive/memory impairment, catalepsy, and extrapyramidal symptoms.
Sources: en.wikipedia.org
Koya-dofu (kōya-dōfu, 高野豆腐 in Japanese) is a freeze-dried type also known as kōri tofu (凍り豆腐, "frozen tofu"). Originally from Mount Kōya, a center of Japanese Buddhism famed for its shōjin ryōri, or traditional Buddhist vegetarian cuisine. It is said that the method of koya-dofu was discovered by accident by leaving tofu outdoors in the winter season. It is sold in freeze-dried blocks or cubes in Japanese markets. It is typically simmered in dashi, sake or mirin and soy sauce. In shōjin ryōri, vegetarian kombu dashi, made from seaweed, is used. When prepared in the usual manner, it has a spongy texture and a mildly sweet or savory flavor. The taste and flavor depend on what soup or cooking stock it was simmered in. A similar form of freeze-dried tofu, in smaller pieces, is found in instant soups (such as miso soup), in which the toppings are freeze-dried and stored in sealed pouches. Shimidōfu (凍み豆腐) is mainly consumed in the Tohoku region. While koya-dofu is made by shade-drying, shimidofu is made by sun-drying.
=== Pharmacodynamics === Mestanolone is an AAS, with both androgenic and anabolic effects. It is very similar in its effects to androstanolone (dihydrotestosterone; DHT), and can be thought of as an orally active version of this AAS. Due to inactivation by 3α-hydroxysteroid dehydrogenase (3α-HSD) in skeletal muscle, mestanolone is described as a very poor anabolic agent, similarly to androstanolone and mesterolone. As mestanolone is 5α-reduced, it cannot be aromatized and hence has no propensity for estrogenic side effects such as gynecomastia. The drug also has no progestogenic activity. Like other 17α-alkylated AAS, mestanolone is hepatotoxic.
Mahathir's heavy-industrialisation programme also included Perwaja Steel, established in 1982 as a government-backed project to develop a domestic steel industry. The company subsequently accumulated substantial losses despite continued government support; a 2024 study in the Malaysian Journal of Economic Studies reported accumulated losses of RM9.9 billion between 1982 and its privatisation in 1996, rising to RM15 billion by the time operations ceased in 1999. Mahathir later described Perwaja as a miscalculation on his part while defending the broader record of his industrial policies. On the economic front, Mahathir inherited the New Economic Policy from his predecessors, which was designed to improve the economic position of the bumiputera—Malaysia's Malays and Indigenous peoples—via targets and affirmative action in areas such as corporate ownership and university admission. Like many of his economic liberal contemporaries such as British prime minister Margaret Thatcher, Mahathir actively pursued privatisation of government enterprises from the early 1980s. Mahathir believed this would provide economic opportunities for bumiputera and their businesses. His government privatised airlines, utilities and telecommunication firms, accelerating to a rate of about 50 privatisations a year by the mid-1990s. Privatisation generally improved the working conditions of Malaysians in privatised industries and raised significant revenue for the government.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.